Bispecific antibodies (BsAbs) are antibodies with two binding sites directed at two different
antigens or two different epitopes on the same antigen. The clinical therapeutic effects of …

As the most commonly occurring cancer in women worldwide, breast cancer poses a
formidable public health challenge on a global scale. Breast cancer consists of a group of …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in
modern drug development. By harnessing the powers of both cytotoxic chemotherapy and …

The human epidermal growth factor receptor (EGFR) family consists of four members that
belong to the ErbB lineage of proteins (ErbB1–4). These receptors consist of a glycosylated …

Human epidermal growth factor receptor 2 (HER2) and HER3 form a potent pro-oncogenic
heterocomplex,–upon binding of growth factor neuregulin-1β (NRG1β). The mechanism by …

ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …

Human epidermal growth factor receptor 2 (HER2) amplification/overexpression is an
effective therapeutic target in breast and gastric cancer. Although HER2 positivity has been …

Targeted anticancer drugs block cancer cell growth by interfering with specific signaling
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …

Although it is broadly agreed that the improved treatment of patients with cancer will depend
on a deeper molecular understanding of the underlying pathogenesis, only a few examples …